INTERVENTION AT THE WHO EXPERT COMMITTEE ON THE SELECTION AND USE OF ESSENTIAL MEDICINES

27 March 2017

PATENT HOLDERS

Licences Sub- Licences Medicines

GENERIC MANUFACTURERS

PEOPLE NEEDING ACCESS TO HIV, HCV AND TB MEDICINES

IN DEVELOPING COUNTRIES

ROYALTIES

THE MEDICINES PATENT POOL MODEL

The MPP is funded by

MPP AND THE EML

WHO EML MEDICINES LICENSED TO THE

MPP

Abacavir (ABC) (paediatrics)

ABC/3TC

Atazanavir (ATV)

Daclatasvir (DCV)

Lopinavir/ritonavir (LPV/r)

Ritonavir (RTV)

Tenofovir disoproxil fumarate (TDF)

TDF/FTC

TDF/FTC/EFV

Valganciclovir * (special access agreement)

MPP has licences on 9 medicines included in the WHO Model List

of Essential Medicines; plus a special access agreement on 1.

EXAMPLE OF HCV MEDICINE DACLATASVIR (DCV)

Following inclusion of DCV in the WHO EML, MPP and BMS

announced a licence to enable generic supply in 112 countries.

EXAMPLE OF HIV MEDICINE DOLUTEGRAVIR (DTG)

Committee will be considering inclusion in the WHO EML this week.

Multiple manufacturers have already filed for registration.

Recently, WHO* and Lancet Commission** recommended that consideration be given to expanding the patent pooling model to all patented essential medicines

MPP beginning study to explore feasibility, desirability and potential public health impact

Process will include consultations with key stakeholders (e.g. governments, experts, pharmaceutical industry and civil society)

EXPLORING EXPANSION INTO PATENTED ESSENTIAL MEDICINES

* WHO Submission to the UN SG High Level Panel on Access to Medicines

** Lancet Commission on Essential Medicines Policies

THANK YOU